)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Pila Pharma
Pila Pharma (PILA) investor relations material
Pila Pharma Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary10 Feb, 2026
Executive summary
Refocused development strategy in 2025 to position TRPV1 antagonist XEN-D0501 as a novel oral treatment for obesity, with additional plans for diabetes and pain indications.
Successfully completed an oversubscribed rights issue, raising SEK 29.9 million before costs, supporting preclinical and clinical development.
Initiated preclinical obesity studies and advanced preparations for clinical trials in obesity, diabetes, and erythromelalgia.
Expanded Scientific Advisory Board and strengthened leadership shareholding.
Financial highlights
Operating income for 2025 was TSEK 1,127, up from TSEK 790 year-over-year.
Operating result (EBIT) for 2025 was TSEK -7,894, compared to TSEK -8,109 in 2024.
Net loss for 2025 was TSEK -16,863, widening from TSEK -11,241 in 2024.
Earnings per share for 2025 were SEK -0.62, compared to SEK -0.30 in 2024.
Cash at year-end was TSEK 15,897, up from TSEK 4,892 at the end of 2024.
Outlook and guidance
Cash runway extends into 2027, enabling continued development in obesity, diabetes, and erythromelalgia.
Next steps include submission of clinical trial applications for obesity and erythromelalgia in early 2026.
Focus remains on generating human proof-of-concept data to attract pharma partnerships.
Preclinical obesity study outcome impact
Erythromelalgia: path to faster revenue?
TO2 warrant exercise outlook and funding
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Pila Pharma
- SEK 10M raised, Phase 2a trial prep, new CEO, improved results, and rising investor interest.PILA
Q2 202423 Jan 2026 - Preparing a dose escalation trial for diabetes/obesity, with expanded pipeline and active investor outreach.PILAInvestor Update18 Jan 2026
- R&D and funding ramped up for a unique obesity drug, with stable liquidity and net loss.PILAQ4 202424 Dec 2025
- Oversubscribed SEK 29.9M rights issue funds obesity drug studies, with results due by early 2026.PILAQ2 202523 Nov 2025
- Oral TRPV1 drug for diabetes and obesity advances, with new funding and pivotal studies ahead.PILAInvestor Update20 Nov 2025
Next Pila Pharma earnings date
Q2 202627 Aug, 2026
Pila Pharma
Next Pila Pharma earnings date
Q2 202627 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage